Inhibikase Therapeutics Inc (IKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2018 | |
| Cash Flows From Operating Activities | ||
| Net Income | -5,723 | -2,152 |
| Other Working Capital | 1,632 | 1,516 |
| Other Operating Activity | 3,753 | 1,351 |
| Operating Cash Flow | $-338 | $715 |
| Cash Flows From Investing Activities | ||
| Other Investing Activity | 0 | 87 |
| Investing Cash Flow | $0 | $87 |
| Cash Flows From Financing Activities | ||
| Other Financing Activity | -23 | -439 |
| Financing Cash Flow | $-23 | $-439 |
| Beginning Cash Position | 380 | 17 |
| End Cash Position | 19 | 380 |
| Net Cash Flow | $-361 | $363 |
| Free Cash Flow | ||
| Operating Cash Flow | -338 | 715 |
| Free Cash Flow | -338 | 715 |